OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA ≥20 NG/ML OR BIOPSY GLEASON SCORE ≥8) WITH RADICAL PROSTATECTOMY AS INITIAL STEP: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS
Steven Joniau, Markus Graefen(Eppendorf (Germany)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Jochen Walz(Institut Paoli-Calmettes), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Gontero(Fondazione Ricerca Molinette), Kathy Vander Eeckt, Martin Spahn(Universitätsklinikum Würzburg), A Tizzani(University of Turin), D. Frohneberg(Städtisches Klinikum Karlsruhe), Hendrik Isbarn(Universität Hamburg), Fritz H. Schröder(Meertens Institute), Chris H. Bangma(Erasmus University Rotterdam), Paul Van Cangh, Pia Bader(Städtisches Klinikum Karlsruhe), Chao‐Yu Hsu(National Chung Hsing University)
Cited by 0
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
|The Lancet|2005|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k